On September 10, 2026, TGA alerted consumers that 23 batches of Nutra-Life and Musashi products were manufactured using sucralose instead of thaumatin.
TGA makes an important distinction:
Sucralose is permitted in these products and the products remain safe to consume according to their directions. Consumers do not need to take action.
So why does the event matter?
Because the actual product no longer matches its approved/declared labeling.
The labels:
- omit the required “contains sucralose” declaration;
- in some cases state that the product contains natural sweeteners or no artificial sweeteners.
That is a classic example of a compliance failure even where toxicological risk is minimal.
Free Download – U.S. Dietary Supplement Label Compliance Audit Checklist
Free Download – Food & Dietary Supplement Ingredient Substitution Change-Control Form
Free Download – Food & Dietary Supplement Natural Claims Verification Checklist
Free Download Food & Dietary Supplement Master Formula vs Batch Record Reconciliation Checklist
Safety and compliance are different questions
Quality investigations sometimes make this mistake:
“The substituted material is safe, therefore there is no problem.”
That is incomplete.
Regulated product quality asks multiple independent questions:
Is it safe?
Is it manufactured according to the approved formula?
Does the batch record accurately reflect reality?
Does the label describe the product correctly?
Do claims remain truthful?
A “safe” substitution can still fail several of those tests.
What may have gone wrong?
TGA’s public notice does not establish the specific root cause.
A manufacturer investigating this type of event would normally consider possibilities such as:
- material selection error;
- warehouse picking error;
- supplier or material-code confusion;
- incorrect master manufacturing record;
- label/formula mismatch;
- change-control failure;
- ERP/master-data error.
The point is not to guess which occurred here.
The point is that the investigation should determine how 23 batches could be made before the discrepancy was intercepted.
Why batch-record review should detect formulation mismatches
A batch record should make it possible to reconcile:
approved formula → dispensed material → actual batch → released label.
If thaumatin is specified but sucralose is dispensed, there should ideally be controls capable of detecting the discrepancy before release.
Those controls may include:
- barcode scanning;
- independent dispensing verification;
- material status checks;
- electronic batch-record rules;
- QA review.
Claims create another compliance layer
The problem becomes more significant when labels say:
natural sweeteners
or
no artificial sweeteners
while the formulation actually includes an artificial sweetener.
Now the event crosses from formulation accuracy into claim substantiation.
Marketing statements need to remain synchronized with manufacturing reality.
Change control is the missing bridge in many organizations
Imagine R&D legitimately decides to replace thaumatin with sucralose.
That change is not merely a formulation-development decision.
It may trigger:
regulatory assessment → specification changes → master batch record → label changes → claims review → artwork → inventory management → implementation date.
If one function moves ahead before the others, the company can manufacture a perfectly safe—but noncompliant—product.
What supplement and listed-medicine companies should review
Run a quick audit around:
- formulation-to-master-record alignment;
- raw-material codes;
- dispensing controls;
- supplier change controls;
- artificial-sweetener declarations;
- “natural” claims;
- artwork master data;
- QA batch-release checks.
Pay extra attention where ingredients have similar functions and could plausibly be substituted.